ArticleInvestigative ophthalmology & visual science2025
Targeted siRNA Delivery Against RUNX1 Via tFNA: Inhibiting Retinal Neovascularization and Restoring Vessels Through Dll4/Notch1 Signaling.
Article in Investigative ophthalmology & visual science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To assess the efficacy of tetrahedral framework nucleic acids (tFNAs) as a delivery system for small interfering RNA (siRNA) targeting RUNX1 (siRUNX1) in inhibiting retinal neovascularization (RNV) and restoring vascular integrity via the Dll4/Notch1 signaling pathway. Methods: tFNAs and tFNAs-siRUNX1 were synthesized using annealing of single-stranded DNAs and characterized by PAGE and high-performance capillary electrophoresis. Human umbilical vein endothelial cells were treated under hypoxic conditions with tFNAs-siRUNX1, and cellular uptake was evaluated using fluorescence microscopy and flow cytometry. Angiogenesis was assessed through EdU proliferation, tube formation, and wound-healing assays. In vivo experiments used oxygen-induced retinopathy (OIR) and laser-induced choroidal neovascularization (CNV) models in mice, with subsequent imaging by optical coherence tomography (OCT) and fundus fluorescence angiography. Gene and protein expression were analyzed by RT-PCR and Western blotting, focusing on the Dll4/Notch1 pathway and apoptosis markers. Results: tFNAs-siRUNX1 effectively inhibited endothelial cell proliferation, migration, and tube formation in vitro. In OIR and CNV models, it reduced neovascularization, nonperfusion areas, and vascular leakage. The mechanism involved modulation of the Dll4/Notch1 pathway, with decreased Dll4, Notch1, and Hes1 and increased Nts expression. tFNAs-siRUNX1 also reduced endothelial cell apoptosis via the Bcl-2/Bax pathway. Conclusions: tFNAs-siRUNX1 is a promising delivery system for targeting RNV, inhibiting neovascularization, and restoring retinal vascular integrity, providing a potential therapeutic alternative to anti-VEGF treatments.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.